New Two-Pronged attack tested for Tough-to-Treat prostate cancer
NCT ID NCT07115446
Summary
This early-stage study is testing the safety and side effects of a new two-drug combination for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The trial will enroll about 63 participants to find the highest dose they can tolerate. The goal is to see if combining a targeted drug delivery system with a protein-destroying therapy can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.